Reversible Contraceptive Potential of FDA Approved Excipient N, N-Dimethylacetamide in Male Rats.
BET inhibitor
bromodomain (BRD)
excipient
male contraception
rat
reproduction
Journal
Frontiers in physiology
ISSN: 1664-042X
Titre abrégé: Front Physiol
Pays: Switzerland
ID NLM: 101549006
Informations de publication
Date de publication:
2020
2020
Historique:
received:
31
08
2020
accepted:
23
10
2020
entrez:
26
11
2020
pubmed:
27
11
2020
medline:
27
11
2020
Statut:
epublish
Résumé
Development of an effective male contraceptive agent remains a challenge. The present study evaluates the potential of N, N-Dimethylacetamide (DMA), a FDA approved excipient as a male contraceptive agent. Male Sprague Dawley rats injected with DMA for a period of 8 weeks (one injection per week) showed a significant alteration of reproductive parameters. Furthermore, DMA treated animals showed complete infertility in a dose dependent manner, as no pups were born despite proper mating between females and DMA treated males. However, stopping the DMA treatment for a period of 8 weeks (after the initial treatment) restored the reproductive parameters to normal. Moreover, the fertility was resumed to normal as pups were born in the groups where DMA treatment was halted after initial DMA treatment. All these changes had no effect on the level of reproductive hormones FSH, LH and testosterone. Taken together, our results indicate that DMA acts in a reversible and non-hormonal manner to achieve contraception in rats. Therefore, repurposing the use of DMA could lead in a short time to an inexpensive and safer male contraceptive option.
Identifiants
pubmed: 33240111
doi: 10.3389/fphys.2020.601084
pmc: PMC7683412
doi:
Types de publication
Journal Article
Langues
eng
Pagination
601084Informations de copyright
Copyright © 2020 Khera, Ghayor, Lindholm, Pavlova, Atanassova and Weber.
Références
Med Oncol. 1999 Sep;16(3):166-76
pubmed: 10523796
Indian J Urol. 2013 Jan;29(1):12-5
pubmed: 23671357
Lancet. 1990 Oct 20;336(8721):955-9
pubmed: 1977002
Physiol Rev. 2016 Jan;96(1):1-17
pubmed: 26537427
Cancer Chemother Pharmacol. 2013 Nov;72(5):1149-55
pubmed: 24036908
FASEB J. 2009 Dec;23(12):4218-30
pubmed: 19692648
J Clin Oncol. 2007 May 1;25(13):1772-8
pubmed: 17470868
PLoS One. 2017 Jul 27;12(7):e0182041
pubmed: 28750087
J Urol. 1991 Mar;145(3):505-11
pubmed: 1997700
Curr Opin Urol. 2010 Nov;20(6):520-4
pubmed: 20808223
BJU Int. 1999 Sep;84(4):475-81
pubmed: 10468765
Am J Chin Med. 2015;43(6):1231-46
pubmed: 26446204
Arzneimittelforschung. 1976;26(8):1581-3
pubmed: 1036956
Am J Reprod Immunol. 1994 Mar-Apr;31(2-3):69-76
pubmed: 8049027
Expert Rev Mol Med. 2011 Sep 13;13:e29
pubmed: 21933453
Development. 2007 Oct;134(19):3507-15
pubmed: 17728347
Chemosphere. 2020 Oct;256:127001
pubmed: 32447106
Toxicol Appl Pharmacol. 2016 Jun 1;300:47-54
pubmed: 27078884
Clin Rev Allergy Immunol. 2019 Jun;56(3):269-277
pubmed: 28653246
Am J Mens Health. 2017 Jul;11(4):1182-1189
pubmed: 26206159
BMC Public Health. 2013 Feb 13;13:133
pubmed: 23406327
Cell. 2012 Aug 17;150(4):673-84
pubmed: 22901802
Drugs. 2019 Jan;79(1):11-20
pubmed: 30588563
Stud Fam Plann. 2014 Sep;45(3):301-14
pubmed: 25207494
J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Jul 11;838(2):129-34
pubmed: 16725388
Sci Rep. 2017 Feb 08;7:42108
pubmed: 28176838
Curr Top Dev Biol. 2013;102:293-326
pubmed: 23287038